Docosanol
Abreva (docosanol) is a small molecule pharmaceutical. Docosanol was first approved as Abreva on 2000-07-25. It is used to treat blister in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Abreva (generic drugs available since 2018-11-19)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Docosanol
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ABREVA | GSK | N-020941 OTC | 2000-07-25 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
abreva | OTC monograph final | 2023-05-19 |
cold sore fever blister treatment | ANDA | 2023-06-06 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
blister | — | D001768 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
2 clinical trials
View more details

Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | 1 | — | 1 | 2 |
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 1 | — | — | 1 |
Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | 1 | — | — | 1 |
Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | DOCOSANOL |
INN | — |
Description | Docosan-1-ol is a long-chain primary fatty alcohol that is docosane substituted by a hydroxy group at position 1. It has a role as an antiviral agent. It is a long-chain primary fatty alcohol and a fatty alcohol 22:0. It derives from a hydride of a docosane. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCCCCCCCCCCCCCCCCCCCCCO |
Identifiers
PDB | — |
CAS-ID | 661-19-8 |
RxCUI | 594680 |
ChEMBL ID | CHEMBL1200453 |
ChEBI ID | 31000 |
PubChem CID | 12620 |
DrugBank | DB00632 |
UNII ID | — |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:

Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 356 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions

Mock data
Subscribe for the real data
Subscribe for the real data
786 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more